SOCS3 and prostate cancer: The suppressor of cytokine signaling 3 (SOCS3) has been proven to inhibit cancer in breast cancer [48], hepatocellular carcinoma [49], small-cell lung cancer [50], prostate cancer [51], and other tumors, while IL-6/STAT3 signaling can induce SOCS3 methylation through DNA methyltransferase 1 (DNMT1) [47], which may promote the growth and metastasis of pancreatic cancer in vitro and in vivo.